How 5 drugmakers fared in 2022

Here's how five of the biggest pharmaceutical companies did financially in 2022:

Pfizer saw an all-time high with its annual revenue as it raked in $100.3 billion. For 2023, the vaccine-maker said it expects to make between $67 billion and $71 billion amid waning demand for its COVID-19 vaccine and COVID-19 drug Paxlovid. 

Johnson & Johnson saw sales of $94.9 billion, a 1.3 percent increase from its 2021 figure. About half of those earnings are from the U.S. Overall, its pharmaceutical business made $52.6 billion, its medical tech segment earned $27.4 billion and its consumer health business got $15 billion. 

Merck's sales totaled $59.3 billion, amounting to a 22 percent increase since 2021. Some of its best-selling products included its COVID-19 antiviral Lagevrio and cancer drug Keytruda. 

Bristol-Myers Squibb reported earning $46.2 billion. When adjusted to foreign exchange rates, it made 3 percent more than 2021. In the U.S., its revenue increased 9 percent to $31.8 billion. 

Biogen earned $10.2 billion in 2022, a 7.4 percent decrease from the year prior. The company said its losses were "driven primarily by cost saving initiatives." Biogen said investors should "expect mid-single digit revenue decline" in 2023. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like